Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report

Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2019